# A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer

> **NCT00625430** · PHASE1 · UNKNOWN · sponsor: **Biotech Equity Partners Pty Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine

## Key facts

- **NCT ID:** NCT00625430
- **Lead sponsor:** Biotech Equity Partners Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2011-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625430, "A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00625430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*